Personalized Medicines Market Valued at USD 900 Billion, Poised for USD 2.12 Trillion by 2034 - SRI

London, UK - August 2026 | Strategic Revenue Insights Inc. - Chronic diseases now account for 71% of deaths worldwide, according to the World Health Organization, a statistic that is putting sustained pressure on healthcare systems to move beyond one-size-fits-all treatment toward therapies matched to an individual's genetic and biological profile. According to a new report from Strategic Revenue Insights, the personalized medicines market was valued at USD 900.0 billion in 2025 and is projected to reach USD 2.12 trillion by 2034, growing at a CAGR of 10.00% during the forecast period. The findings are led by analyst Anirudh Singh, and the report draws on primary interviews with hospital and cancer center clinicians, diagnostic laboratory operators, and pharmaceutical and biotechnology executives, combined with secondary research spanning Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.

Key Takeaways

• The market is valued at USD 900.0 billion in 2025 and is forecast to reach USD 2.12 trillion by 2034, a CAGR of 10.00%.
• Personalized Therapeutics is the largest segment, while AI-Driven Analytics is the fastest-growing segment.
• Integration of genomics and AI-driven analytics is revolutionizing precision in personalized healthcare delivery.
• North America leads the market on the strength of advanced healthcare infrastructure and high adoption, while Asia Pacific is the fastest-growing region.
• Roche, Illumina, and Thermo Fisher Scientific are the top competitors named in the report.

Full report access: https://www.strategicrevenueinsights.com/industry/personalized-medicines-market

A Global Health Burden Reshapes What "Treatment" Means

The World Health Organization's finding that chronic diseases cause 71% of deaths globally is more than a statistic in this report, it is functioning as a structural driver of the entire market. As populations age and chronic disease incidence rises, healthcare systems are under growing pressure to move away from generalized treatment protocols toward therapies tailored to a patient's genetic profile and health condition, a shift that personalized medicine is directly positioned to serve. Advancements in genomics and biomarker-based testing are making that shift practical by allowing clinicians to identify specific genetic markers and build tailored treatment plans around them.

Layered on top of this clinical driver is a technological one: AI-driven analytics is changing how personalized medicines are developed and delivered, enabling more accurate diagnostics and more precisely targeted therapies. That same analytics capability is also fueling a parallel expansion into personalized nutrition and wellness, as consumers increasingly seek solutions tailored to their own health needs rather than generic recommendations, supported by advances in biomarker-based testing that can identify individual nutritional requirements.

None of this is without friction. The complex and evolving regulatory landscape for personalized medicines can slow market entry and raise development costs, and the high price of personalized treatments remains a real barrier to accessibility for many patients and healthcare systems, leaving the market to compete against cheaper, more widely available conventional treatment options even as demand for precision care grows.

Market Segmentation

By product type, Personalized Therapeutics is the largest segment, driven by demand for targeted treatments that improve patient outcomes, while Personalized Nutrition & Wellness is the fastest-growing segment as consumers seek tailored solutions for their individual health needs.

By technology, Genomics & Sequencing is the largest segment, underpinning the identification of genetic markers used to build tailored treatment plans, while AI-Driven Analytics is the fastest-growing segment as it enables more accurate diagnostics and more precisely targeted therapies.

By application, Oncology is the largest segment given the rising prevalence of cancer and demand for personalized treatment options, while Neurology & Psychiatry is described as a rapidly growing segment as targeted therapies expand into these conditions.

By end use, Hospitals & Cancer Centers represent the largest segment as the primary providers of personalized healthcare services, while Academic Research Institutes are a rapidly growing segment given their role in developing and advancing personalized medicine.

Regional Outlook

North America is the leading region in the personalized medicines market, supported by advanced healthcare infrastructure and high adoption of personalized medicine. Asia Pacific is the fastest-growing region, driven by increasing healthcare investments. Europe, Latin America, and Middle East & Africa round out the report's regional coverage as personalized medicine adoption continues to expand across these markets.

Competitive Landscape

Roche, Illumina, and Thermo Fisher Scientific lead the competitive landscape. Roche is known for its innovative diagnostic solutions and personalized healthcare offerings, leveraging its expertise in genomics and biomarker-based testing to develop targeted therapies. Illumina is a leader in sequencing technologies, providing advanced genomic solutions that enable personalized treatment options. Thermo Fisher Scientific offers a broad portfolio spanning genomic testing solutions, biomarker-based assays, and AI-driven analytics that support more precise, personalized treatment decisions. The report also names Qiagen, Novartis, AstraZeneca, Myriad Genetics, Exact Sciences, Guardant Health, and Tempus AI among other active players investing in research, development, and strategic partnerships.

Market Restraints

Two factors stand out as the primary restraints on market growth. First, the complex and evolving regulatory landscape for personalized medicines can create barriers to market entry and increase the time and cost of bringing new products to market. Second, the high cost of personalized medicines can limit accessibility and adoption, leaving the market exposed to competition from cheaper, more widely available traditional treatment options.

Related Reports

https://www.strategicrevenueinsights.com/industry/ai-in-waste-management-market

https://www.strategicrevenueinsights.com/industry/air-quality-monitoring-system-market

https://www.strategicrevenueinsights.com/industry/arcade-games-center-market

https://www.strategicrevenueinsights.com/industry/asset-performance-management-market

https://www.strategicrevenueinsights.com/industry/augmented-reality-market

Frequently Asked Questions

How big is the personalized medicines market?

The market was valued at USD 900.0 billion in 2025 and is projected to reach USD 2.12 trillion by 2034, growing at a CAGR of 10.00%.

What is the fastest-growing segment in personalized medicines?

AI-Driven Analytics is the fastest-growing technology segment, and Personalized Nutrition & Wellness is the fastest-growing product type segment, both driven by rising demand for tailored, data-driven healthcare.

Which region leads the personalized medicines market?

North America is the leading region due to its advanced healthcare infrastructure and high adoption of personalized medicine, while Asia Pacific is the fastest-growing region.

Who are the top companies in the personalized medicines market?

The leading companies named in the report are Roche, Illumina, and Thermo Fisher Scientific, alongside other named players including Qiagen, Novartis, AstraZeneca, Myriad Genetics, Exact Sciences, Guardant Health, and Tempus AI.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., part of SRI Consulting Group Ltd, is a London-headquartered market intelligence firm that helps organizations across industries and geographies make evidence-based revenue and strategy decisions. The firm produces syndicated research reports and customized consulting engagements built on rigorous market sizing, forecasting, and competitive benchmarking, drawing on a globally connected team of analysts and consultants.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44-787-740-3352

Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom

Corporate Websites:

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com

https://strategicrevenueinsights.blog/

https://medium.com/@strategic-revenue-insights.inc

https://www.strategicrevenueinsights.com/press-releases